167 related articles for article (PubMed ID: 36970171)
1. The predictive value of partial
Torre M; Wen PY; Iorgulescu JB
Neurooncol Pract; 2023 Apr; 10(2):126-131. PubMed ID: 36970171
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of MGMT promoter methylation on the survival of TMZ treated
Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
[TBL] [Abstract][Full Text] [Related]
3. MGMT promoter methylation in 1p19q-intact gliomas.
Kinslow CJ; Siegelin MD; Iwamoto FM; Gallitto M; Neugut AI; Yu JB; Cheng SK; Wang TJC
J Neurooncol; 2024 Jan; 166(1):73-78. PubMed ID: 38114801
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of
Lam K; Eldred BSC; Kevan B; Pianka S; Eldred BA; Zapanta Rinonos S; Yong WH; Liau LM; Nghiemphu PL; Cloughesy TF; Green RM; Lai A
Neurooncol Adv; 2022; 4(1):vdac030. PubMed ID: 35386566
[TBL] [Abstract][Full Text] [Related]
5. O
Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
[TBL] [Abstract][Full Text] [Related]
6. Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.
Kavouridis VK; Ligon KL; Wen PY; Iorgulescu JB
J Neurooncol; 2022 May; 158(1):111-116. PubMed ID: 35474499
[TBL] [Abstract][Full Text] [Related]
7. Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation.
Incekara F; van der Voort SR; Dubbink HJ; Atmodimedjo PN; Nandoe Tewarie R; Lycklama G; Vincent AJPE; Kros JM; Klein S; van den Bent M; Smits M
Front Oncol; 2020; 10():596. PubMed ID: 32477929
[No Abstract] [Full Text] [Related]
8. Prognostic role and interaction of TERT promoter status, telomere length and MGMT promoter methylation in newly diagnosed IDH wild-type glioblastoma patients.
Giunco S; Padovan M; Angelini C; Cavallin F; Cerretti G; Morello M; Caccese M; Rizzo B; d'Avella D; Puppa AD; Chioffi F; De Bonis P; Zagonel V; De Rossi A; Lombardi G
ESMO Open; 2023 Jun; 8(3):101570. PubMed ID: 37230028
[TBL] [Abstract][Full Text] [Related]
9. Telomerase reverse transcriptase promoter mutation- and O
Gramatzki D; Felsberg J; Hentschel B; Wolter M; Schackert G; Westphal M; Regli L; Thon N; Tatagiba M; Wick W; Schlegel U; Krex D; Matschke J; Roth P; Suresh MP; Kamp MA; Rushing EJ; Pietsch T; von Deimling A; Sabel M; Loeffler M; Weller M; Reifenberger G
Eur J Cancer; 2021 Apr; 147():84-94. PubMed ID: 33631540
[TBL] [Abstract][Full Text] [Related]
10. Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study.
Caccese M; Simonelli M; Villani V; Rizzato S; Ius T; Pasqualetti F; Russo M; Rudà R; Amoroso R; Bellu L; Bertorelle R; Cavallin F; Dipasquale A; Carosi M; Pizzolitto S; Cesselli D; Persico P; Casini B; Fassan M; Zagonel V; Lombardi G
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626029
[TBL] [Abstract][Full Text] [Related]
11. Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients.
Radke J; Koch A; Pritsch F; Schumann E; Misch M; Hempt C; Lenz K; Löbel F; Paschereit F; Heppner FL; Vajkoczy P; Koll R; Onken J
Acta Neuropathol Commun; 2019 Jun; 7(1):89. PubMed ID: 31167648
[TBL] [Abstract][Full Text] [Related]
12. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
[TBL] [Abstract][Full Text] [Related]
13. MGMT promoter methylation in 1p19q-intact gliomas.
Kinslow C; Siegelin MD; Iwamoto FM; Gallitto M; Neugut AI; Yu JB; Cheng SK; Wang TJC
Res Sq; 2023 Oct; ():. PubMed ID: 37886555
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI
Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342
[TBL] [Abstract][Full Text] [Related]
15. Association of
Kim M; Yoo J; Chang JH; Kim SH
Anticancer Res; 2022 Jan; 42(1):335-341. PubMed ID: 34969742
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
17. Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas.
Gessler F; Bernstock JD; Braczynski A; Lescher S; Baumgarten P; Harter PN; Mittelbronn M; Wu T; Seifert V; Senft C
Neurosurgery; 2019 Jan; 84(1):190-197. PubMed ID: 29617848
[TBL] [Abstract][Full Text] [Related]
18. Pyrosequencing Analysis of O-6-Methylguanine-DNA Methyltransferase Methylation at Different Cut-Offs of Positivity Associated with Treatment Response and Disease-Specific Survival in Isocitrate Dehydrogenase-Wildtype Grade 4 Glioblastoma.
Silva FFVE; Di Domenico M; Caponio VCA; Pérez-Sayáns M; Camolesi GCV; Rojo-Álvarez LI; Ballini A; García-García A; Padín-Iruegas ME; Suaréz-Peñaranda JM
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203783
[TBL] [Abstract][Full Text] [Related]
19. Correlation of commercially available quantitative
Dovek L; Nguyen NT; Ozer BH; Li N; Elashoff RM; Green RM; Liau L; Nghiemphu PL; Cloughesy TF; Lai A
Neurooncol Pract; 2019 May; 6(3):194-202. PubMed ID: 31386024
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
